Publication:
Serum Tumour Markers in Renal Failure

dc.contributor.authorArik N.
dc.contributor.authorAdam B.
dc.contributor.authorAkpolat T.
dc.contributor.authorHaşil K.
dc.contributor.authorTabak S.
dc.date.accessioned2020-06-21T09:19:41Z
dc.date.available2020-06-21T09:19:41Z
dc.date.issued1996
dc.departmentOMÜen_US
dc.department-tempArik, N., Department of Nephrology, Ondokuz Mayis University, Samsun, Turkey -- Adam, B., Department of Biochemistry, Ondokuz Mayis University, Samsun, Turkey -- Akpolat, T., Department of Nephrology, Ondokuz Mayis University, Samsun, Turkey -- Haşil, K., Department of Nephrology, Ondokuz Mayis University, Samsun, Turkey -- Tabak, S., Department of Public Health, Ondokuz Mayis University, Samsun, Turkey --en_US
dc.description.abstractIn order to assess the clinical value of six tumour markers in pre-dialysis patients with chronic renal failure as well as in patients on regular haemodialysis, we studied these markers in 35 predialysis patients, 35 patients on chronic haemodialysis and 35 healthy controls. Serum squamous cell antigen (SCC), CA 19.9, and CA 125 levels were found to be elevated in the uraemic groups as compared to the normal controls. Carcinoembryonic antigen (CEA), alpha foetoprotein (AFP), and prostate-specific antigen (PSA) levels were within normal limits in all groups.en_US
dc.identifier.doi10.1007/BF02550974
dc.identifier.endpage604en_US
dc.identifier.issn0301-1623
dc.identifier.issue4en_US
dc.identifier.pmid9119652
dc.identifier.startpage601en_US
dc.identifier.urihttps://doi.org/10.1007/BF02550974
dc.identifier.urihttps://hdl.handle.net/20.500.12712/3116
dc.identifier.volume28en_US
dc.language.isoenen_US
dc.publisherKluwer Academic Publishersen_US
dc.relation.journalInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSerum Tumour Markers in Renal Failureen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files